Thursday, June 24, 2010

Editorial

The next issue of Capsule is out with a greater zeal and earnestness to share the clinical experiences of our faculty members. The medical problems of the developing nations are of different nature than that of the developed ones: despite the efforts by leaders of the political and medical fields to bridge the differences. These differences obviously get reflected in the focus of medical research and the resources earmarked for the areas of interests. It may not be an exaggeration that, there is apathy in medical research towards organo phosphorus compound toxicity, which is a major global health problem with more than 200,000 deaths every year. These whopping numbers succumbing to the avoidable disaster requires immediate attention by the medical researchers in developing more effective antidote and arriving at a consensus on a standard of therapy to tranquil the controversy ridden murky waters of oxime therapy.

Capsule features an unusual case of Intravenous Intoxication of Organophosphate Compound and also an interesting case of insulinoma. Addition to the regular features a medical cross word comes to lighten the busy schedule of the physicians. The online version http://jsscapsule.blogspot.com has roused interests of a good lot, but we look forward for your valuable feedbacks to make your CAPSULE much palatable.

With best regards

Dr. Sudharshana Murthy K.A.

Professor & Head, Dept of Medicine

JSSMC & Hospital, Mysore

Dr. Narahari .M.G

Assistant Professor

JSSMC & Hospital, Mysore

Photographs



















1. Release of CAPSULE by Dr.Prem Pais, Dean & Professor Medicine, St.Johns National Academy of Health Sciences, during Medicine Update 2010. Dr.Basavana Gowdappa,Principal,JSSMC,Dr.B.V.Rajagopal,Dr.C.D.SreenivasaMurthy, Dr.K.A.Sudharshanamurthy,Professor & Head Medicine, JSSMC ,Dr.Javeed Nayeem (R-L)






















2. Felicitations to Dr.Basavana Gowdappa, Principal & Professor at Medicine Update 2010 by Sri.K.B.Ganapathi, Editor Star of Mysore




















3. Guest lecture by Dr.K.A.Sudharashanamurthy, Professor & Head Medicine, JSSMC at Medicine Update 2010, MPMRT Mysore

An Unusual Case of Intravenous Intoxication of Organophosphate Compound

Y. S. Ravikumar,K. M Srinath,L. S Adarsh, Ashik K Sasidharan, Nagalakshmi, Akash Medicine VI Unit, JSSMC & Hospital, Mysore.

A 29 year old male, a chronic alcoholic and smoker, with history of previous suicidal attempts and repeated head injuries, reported to emergency department with vague chest discomfort, incessant vomiting and severe pain in left upper and lower limbs of one day duration. Patient was irritable and slightly restless. His pulse was 100/min and regular. BP was 120/80 mmHg. Systemic examination was unremarkable and pupils were normal. ECG was normal. A provisional diagnosis of chronic alcoholism with alcoholic gastropathy and delirium tremens (DT) was considered. Psychiatrist also concurred with the diagnosis of DT. He was treated with PPIs, thiamine and IV fluids. There was no history suggestive of poisoning. However, naso-gastric aspiration was done, which was normal.

His general condition worsened over the next few hours. He developed fever, increased tracheobronchial secretions and started to desaturate. His pupils became constricted. He was immediately intubated and put on ventilator. Possibilities of brain stem encephalitis, pontine hemorrhage and organophosphate compound poisoning were considered.

The serum cholinesterase level was significantly low (730U/l). He was then started on atropine and pralidoxime. There was no history of poisoning forthcoming on repeated enquiries with the family members. His serum cholinesterase level continued to be low on the subsequent days.

Two days after admission, he developed blebs over his left upper limb, which progressed to cellulitis. Surgical opinion was taken and incision and drainage was done. Over the next two weeks his general condition improved and he was weaned off the ventilator. Patient denied having taken organophosphate compound in any form. However, his brother recollected that, he had found a syringe in the patient’s pocket while shifting him to the hospital. Patient was discharged after a few days. During follow up, he was stable and his serum cholinesterase had improved.

Clinical features like pin point pupils, increased tracheobronchial secretions supported by low serum cholinesterase levels and patient having developed cellulitis of left upper limb and RT aspiration being normal, prompted the diagnosis of organophosphate poisoning-by non-enteral route.

The other causes of low serum cholinesterase levels like, chronic anemia, malnutrition, surgical shock, blood dyscrasias, radiation, exposure to phenothiazines, uremia, chronic liver disease and malignant states, were excluded in this case. Decreased cholinesterase levels, which can be familial was excluded by checking cholinesterase levels of the patient’s siblings and mother. Hence this was a case of organophosphate compound poisoning by parenteral route. It always pays when we have a high index of suspicion in patients who are alcoholics, those with previous suicide attempts and those with some knowledge of using drugs.

Here is a brief review of mechanism of Organophosphate compound poisoning and their clinical features

Overview of Organophosphate and Carbamate toxicity
Clinical Syndromes
Acute Toxicity
Generally manifests in minutes to hours.

Evidence of cholinergic excess

SLUDGE = Salivation, Lacrimation, Urination, Defecation, Gastric Emptying

BBB = Bradycardia, Bronchorrhea, Bronchospasm

Respiratory insufficiency can result from muscle weakness, decreased central drive, increased secretions, and bronchospasm.
Intermediate Syndrome
Occurs 24-96 hours after exposure

Bulbar, respiratory, and proximal muscle weakness are prominent features

Generally resolves in 1-3 weeks
Organophosphorous Agent-Induced Delayed Peripheral Neuropathy (OPIDN)
Usually occurs several weeks after exposure

Primarily motor involvement

May resolve spontaneously, but can result in permanent neurologic dysfunction
Diagnostic Evaluation of Acute Toxicity
Atropine challenge if diagnosis is in doubt (1 mg IV in adults, 0.01-0.02 mg/kg in children)

Absence of anticholinergic signs and symptoms (tachycardia, mydriasis, decreased bowel sounds, ordry skin) strongly suggests poisoning with organophosphate or carbamate.

Decreased RBC acetylcholinesterase activity confirms diagnosis

Your browser may not support display of this image.

RBC cholinesterase less than 50% of normal indicates organophosphate toxicity.

Disadvantages of Cholinesterase as an indicator:

Normal cholinesterase level is based on population estimates and there is a wide range of distribution defining the normal levels.

False depression of RBC Cholinesterase level is seen in pernicious anemia, hemoglobinoapthies and antimalarial treatment and blood collected in oxalate tubes.

Though organophosphate poisoning is not a rare event, there are a very few case reports of parenteral OP poisoning. The report by Lyon et al. of a 24-year-old man who injected 1.8 g of malathion intravenously. In that patient serum PChE levels were undetectable for 24 hours after the injection, but the patient had only moderate toxic effects and survived. The apparent half-life of malathion, calculated from the serum concentration data, was of 2.89 hours. There are a few case reports of intramuscular and subcutaneous administration of these insecticides, where in the onset of symptoms would be delayed and persist for a longer duration warranting a longer duration of antidote therapy. An interesting case of intravenous toxicity of OP poisoning with monochrotophos who developed intermediate syndrome and required prolonged ventilation and restarting pralidoxime after the fifth day of intoxication has been reported by Badhe & Sudhakar.

These reports of parenteral intoxication of Organophosphate compound, which usually presents as a sequel of ingestion, cautions the emergency care physician to be on the watch to recognize the systemic manifestations of toxicity, actively look for signs of injection marks, local abscesses on the person. In such cases, the usual practice of gastric lavage or use of activated charcoal takes a backseat. Instead, a debridement of the local collection at the injection site would help eliminating the “depot” of insecticide

References:

1. A Case Report of Intravenous Malathion Injection with Determination of Serum Half-Life. Jack Lyon‌, Howard Taylor‌ and Bruce Ackerman‌. Clinical Toxicology 1987, Vol. 25, No. 3, Pages 243-249.

2. Intravenous organophosphate injection: an unusual way of intoxication. Güven M, Unlühizarci K, Göktaş Z, Kurtoğlu S. Hum Exp Toxicol. 1997 May; 16(5):279-80.

3. An intravenous organophosphate poisoning with intermediate syndrome: An unusual way of intoxication. Ashok Badhe, S Sudhakar Indian Journal of Critical Care Medicine 2006: 10: 3: 191-192

4. Parenteral injection of organophosphate insecticide.Apropos of two cases. Sao Paulo Med.J. vol.112 no.2 Apr/June 1994.

5. Pocket book of Pesticide Poisoning for Physicians 1st Ed- V.V.Pillay CBS Publishers.

!! PROUD MOMENTS !!

Dr.K.A.Sudharshanamurthy,Professor & Head Medicine,JSSH & MC, delivered guest lectures on Febrile Emergencies at MPMRT-Medicine Update 2010,Mysore

and Hypertensive Emergencies at Kodagu under the auspices of IMA.

Dr.Suresh Babu,M delivered guest lecture at Kodagu under the auspices of IMA.

Adjudged the best paper of the platform of State KAPICON 2010 Belagaum

A Study of Cardiac Autonomic Dysfunction in HIV/AIDS Patient

Mahesh,M, Shashidhar,Sudharshan Murthy,K.A.,Basavana Gowdappa,H

Summary

The study was designed to evaluate cardiac autonomic dysfunction in HIV/AIDS patients and its correlation withCD4 count. The study noted significant autonomic dysfunction in both HIV positive without AIDS and HIV positive with AIDS. However, there was no statistically significant correlation with the CD4 level and the presence of autonomic dysfunction.

Adjudged the best in the award paper category of the State KAPICON Belagaum

A STUDY OF GLYCEMIC INDEX OF TEN COMMON INDIAN FRUITS

Premanath,M, Basavanagowdappa,H, Mahesh, M Suresh Babu,M

Summary

The study estimated glycemic index (GI) of ten locally available fruits by an alternate method. The study also demonstrates that, GI of five of the fruits is less than 50 and diabetics can consume them in lesser quantities.

Adjudged the best presented poster of the State KAPICON Belagaum

Hepato Pulmonary Syndrome in Cryptogenic Cirrhosis of Liver - A Case Report

Mahesh .M, Sunil.R, Mohangowda, Srinivas

Interesting Case - Insulinoma

A 50 year old male presented with fatigability and increased appetite of 15 years duration. He reported that, he has to have a meal every 2 – 3 hours or else he would feel tired: tiredness would decrease after food intake. There was no history of weight loss, loose stools or palpitations. There was no history of fever, convulsions or loss of consciousness. He was not a diabetic and he gave no history of any drug intake.

Patient was of good built and afebrile. His vital parameters were stable. He had no thyromegaly, tremors or edema. Systemic examination was clinically normal. Once while the patient was symptomatic in the hospital, his glucose level was checked and was found to be less than 50mg/dl. His symptoms improved with IV dextrose.

He was then evaluated for causes of recurrent hypoglycemia. Causes like insulin or sulfonylurea intake, sepsis, cardiac, renal and hepatic failure were ruled out. He was then evaluated for Insulinoma. C peptide levels was done, which was elevated two fold. MRI abdomen was done. It showed a mass lesion at the tail of the pancreas? A possible diagnosis of Insulinoma was considered.

He was consequently put on continuous intra venous dextrose saline infusion. He is awaiting surgery now.

INSULINOMA

Insulinomas are rare pancreatic islet cell tumors (incidence of 1 case per 250,000 person-years); while most are sporadic, some are associated with the MEN1 syndrome. The characteristic clinical manifestation of an insulinoma is fasting hypoglycemia, (although some patients also have postprandial hypoglycemia), with neuroglycopenic symptoms which may or may not be preceded by sympathoadrenal (autonomic) symptoms. The neuroglycopenic symptoms of insulinoma include confusion, visual change, and unusual behavior. Sympathoadrenal symptoms may include palpitations, diaphoresis, and tremulousness. Amnesia for hypoglycemia is common. The median duration of symptoms before diagnosis was less than 1.5 years in one Mayo Clinic series. However, a few patients had probably been symptomatic for decades. As many as 20 percent of patients had been misdiagnosed with a neurological or psychiatric disorder before the insulinoma was recognized. Seizure disorder is another common misdiagnosis. Weight gain was described in 18 percent of patients. Most insulinoma are solitary and benign. Multiple insulinomas are less common, and tend to be associated with MEN1. Malignant insulinomas are also less common.

The diagnosis of insulinoma is established by demonstrating inappropriately high serum insulin concentrations during a spontaneous or induced episode of hypoglycemia (eg, 72-hour fast).

Imaging techniques are then used to localize the tumor. Accurate preoperative localization of an insulinoma is desirable. The procedures available include spiral CT, arteriography, ultrasonography (transabdominal and endoscopic), and 111-In-pentetreotide imaging. Transabdominal ultrasonography and CT are preferred initial tests, followed by endoscopic ultrasonography or arterial stimulation with hepatic venous sampling when an insulinoma has not been localized by noninvasive techniques.

There are a few disorders in which the biochemical findings simulate those of an insulinoma because they are also associated with primary overproduction of insulin:

  • Familial persistent hyperinsulinemic hypoglycemia of infancy
  • Primary islet-cell hyperplasia (also called nesidioblastosis)
  • Noninsulinoma pancreatogenous hypoglycemia syndrome
  • Post gastric bypass hypoglycemia.

The latter two conditions have the characteristic feature of producing primarily postprandial hypoglycemia.

The recommended initial treatment of patients with benign, solitary insulinoma is the surgical excision of the tumor (Grade 1A). The approach and extent of surgery should be determined based upon tumor location. Patients with multiple insulinomas (typically in the setting of MEN1), the recommended treatment is local excision of any tumors found in the head of the pancreas plus a distal subtotal pancreatectomy (Grade B). Patients with persistent hypoglycemia after surgery in whom solitary or multiple tumors are identified after additional localization procedures; a repeat operation (Grade 1A) is resorted to. In patients whom insulinoma cannot be located during pancreatic exploration, who are not candidates for or refuse surgery, diazoxide therapy for the medical management of hypoglycemia (Grade 2C) is recommended. Diazoxide (which diminishes insulin secretion and is given in divided doses of up to 1200 mg/day) sometimes used for controlling hypoglycemia. However, it can cause marked edema (which may require high doses of loop diuretics) and hirsutism.

Octreotide, an analog of somatostatin , inhibits GH secretion, but in large doses, also inhibits the secretion of TSH, insulin, and glucagon. Octreotide is highly effective in controlling the symptoms associated with glucagonomas, VIPomas, and carcinoid tumors, efficacy is less predictable for symptomatic patients with insulinoma. However, it could be a reasonable choice for patients with persistent hypoglycemia that is refractory to diazoxide. Lanreotide, another somatostatin analog is reported to have similar clinical efficacy as octreotide, and is also available in a long-acting depot form (Lanreotide-SR). Verapamil and phenytoin have also been used with some success. However, none of these drugs are as effective as tumor resection.

A patient with potentially resectable liver-isolated metastatic insulinoma, surgical resection of the hepatic metastases along with the primary tumor (Grade 1B) is the preferred option. Although the majority of cases will not be cured by surgery, given the slow-growing nature of the tumor, extended survival is sometimes possible. Other treatment options for patients with unresectable hepatic-predominant symptomatic metastatic disease include embolization, chemoembolization, radio frequency ablation, and cryoablation. The efficacy of somatostatin analogs for patients with diazoxide-refractory symptomatic hypoglycemia is unpredictable. Octreotide, as well as other systemic therapy approaches (interferon, chemotherapy, targeted radiotherapy) are tried but with variable outcomes. The traditional chemotherapy regimen of choice in malignant insulinomas has been streptozocin and doxorubicin: with objective response rates as high as 69 percent for metastatic islet cell tumors, the true radiologic response rate is probably lower, between 10 and 40 percent. Alternative regimen comprising of orally active alkylating agent temozolomide are being tried.

Novel therapeutic approaches for patients with advanced islet cell tumors include the use of targeted radiotherapy, as well as regimens incorporating inhibitors of angiogenesis, small molecule tyrosine kinase inhibitors, and inhibitors of the mammalian target of rapamycin (mTOR)

There are no evidence-based guidelines for follow-up after resection of a malignant insulinoma. Consensus-derived guidelines from the National Comprehensive Cancer Network following treatment for an islet cell tumor include:

  • Three and six months postresection — History and physical examination, tumor markers,
  • CT/MRI Long-term — History and physical examination with tumor markers every 6 to 12 months for years 1 to 3, and as clinically indicated thereafter. Imaging studies are recommended only as clinically indicated

RE-ARRANGEMENT OF COMMON MEDICAL WORDS GIVES INTERESTING RESULTS!!!

1. He burn art

Heart burn

2. Sons in Park

Parkinson’s

3. It is card

carditis

4. Far in war

Warfarin

5. It is my os

Myositis

6. An end ox

Endoxan

7. Dig it in ox

Digitoxin

8. I add sons

Addisons

9. It is mast

Mastitis

10. Did as i can is

candidiasis

Dr.M.Mahesh, Associate Professor of Medicine